---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-020667"
form_type: "8-K"
ticker: "PVLA"
cik: "0001583648"
company_name: "PALVELLA THERAPEUTICS, INC."
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:36:40.278853+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Palvella Therapeutics raises ~$187.3M in public offering of 1.6M shares at $125/sh

## Summary
- Underwriting agreement with TD Securities, Cantor Fitzgerald, and Stifel for 1,600,000 shares at $125.00 each.
- Underwriters have 30-day option to purchase up to an additional 240,000 shares at same price.
- Net proceeds estimated at $187.3M after underwriting discounts and expenses.
- Proceeds to support QTORIN rapamycin and pitavastatin programs, R&D, and working capital.
- Closing expected on or about February 27, 2026, subject to customary conditions.

## SEC filing metadata
- accession: 0001104659-26-020667
- form_type: 8-K
- ticker: PVLA
- cik: 0001583648
- company_name: PALVELLA THERAPEUTICS, INC.
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583648/000110465926020667/0001104659-26-020667-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583648/000110465926020667/tm2534019d6_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-020667
- JSON: https://secwatch.observer/filing/0001104659-26-020667.json
- Plain text: https://secwatch.observer/filing/0001104659-26-020667.txt

## Key facts
- Material Agreements
  PALVELLA THERAPEUTICS, INC. entered into Underwriting Agreement with TD Securities (USA) LLC, Cantor Fitzgerald & Co. and Stifel, Nicolaus & Company, Incorporated valued at approximately $187.3 million (effective 2026-02-25).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: TD Securities (USA) LLC, Cantor Fitzgerald & Co. and Stifel, Nicolaus & Company, Incorporated
  - Value: approximately $187.3 million
  - Effective: 2026-02-25
  source text: On February 25, 2026, Palvella Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with TD Securities (USA) LLC, Cantor Fitzgerald & Co. and Stifel, Nicolaus & Company, Incorporated, as representatives (the “Representatives”) of the underwriters listed in Schedule A thereto (the “Underwriters”), pursuant to which the Company agreed to issue and sell an aggregate of 1,600,000 shares (the “Firm Shares”) of its common stock, par value $0.001 per share (the “Common Stock”), at a price to the public of $125.00 (the “Offering”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1583648/000110465926020667/0001104659-26-020667-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.